

# Javier Martin-Broto

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1125258/javier-martin-broto-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

143  
papers

6,001  
citations

39  
h-index

75  
g-index

151  
ext. papers

7,786  
ext. citations

6.3  
avg, IF

5.49  
L-index

#	Paper	IF	Citations
143	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101829	2.2	1
142	Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case report. <i>Current Problems in Cancer Case Reports</i> , <b>2022</b> , 6, 100149	0.3	
141	WNT/ECatenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
140	Olaratumab-induced Biomarker Modulation in Sarcomas-Response. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 2094	6.1	
139	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , <b>2021</b> , 10, 2645-2659	4.8	8
138	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISC), and Spanish Group for Research on Sarcomas (GEIS). <i>Annals of</i>	10.3	5
137	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , <b>2021</b> , 127, 2934-2942	6.4	11
136	What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?. <i>Current Opinion in Oncology</i> , <b>2021</b> , 33, 329-335	4.2	
135	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , <b>2021</b> , 92, 493-499	4.3	1
134	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , <b>2021</b> , 6, 100170	6	11
133	A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin. <i>Molecular Oncology</i> , <b>2021</b> , 15, 3691-3705	7.9	0
132	A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. <i>Cancers</i> , <b>2021</b> , 13,	6.6	14
131	The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). <i>Clinical and Translational Oncology</i> , <b>2021</b> , 23, 2489-2496	3.6	0
130	Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2021</b> , 32, 1348-1365	10.3	48
129	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. <i>Journal of Surgical Oncology</i> , <b>2021</b> , 123, 12-23	2.8	2
128	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 132-141	6.1	7
127	SEOM Clinical Guideline of management of soft-tissue sarcoma (2020). <i>Clinical and Translational Oncology</i> , <b>2021</b> , 23, 922-930	3.6	6

126	Sunitinib Exerts Immunomodulatory Activity on Sarcomas Dendritic Cells and Synergizes With PD-1 Blockade. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 577766	8.4	4
125	A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
124	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3861-3866	12.9	2
123	A Novel Gene Fusion in Solitary Fibrous Tumor: A Case Report. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
122	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2173-2181	3.6	1
121	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , <b>2021</b> , 17, 2923-2939	3.6	5
120	Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2166-2172	3.6	9
119	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STs 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 2539-2552	6.1	0
118	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 99, 102259	14.4	1
117	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 99, 102260	14.4	1
116	Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
115	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2178-2186	2.2	57
114	,, and as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
113	Cancer Stem Cells in Soft-Tissue Sarcomas. <i>Cells</i> , <b>2020</b> , 9,	7.9	4
112	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , <b>2020</b> , 5,	6	5
111	New drugs in gastrointestinal stromal tumors. <i>Current Opinion in Oncology</i> , <b>2020</b> , 32, 314-320	4.2	10
110	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , <b>2020</b> , 155, e200397	5.4	14
109	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , <b>2020</b> , 126, 2617-2617	6.4	31

108	Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5801-5808.	18.9	9
107	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 535-541	13.4	17
106	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 456-466	21.7	25
105	International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. <i>Trials</i> , <b>2020</b> , 21, 96	2.8	23
104	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. <i>BMC Cancer</i> , <b>2020</b> , 20, 99	4.8	21
103	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 15-28	3.5	4
102	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1266-1276	27.4	91
101	Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. <i>Cancers</i> , <b>2020</b> , 13,	6.6	6
100	Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 16-17	21.7	2
99	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , <b>2020</b> , 25, e1562-e1573	5.7	3
98	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1506-1517	10.3	39
97	Prognostic Impact of MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
96	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial <b>2020</b> , 8,		29
95	Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. <i>Signal Transduction and Targeted Therapy</i> , <b>2020</b> , 5, 195	21	6
94	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 957-963	3.5	3
93	Impact of Wnt/ECatenin Inhibition on Cell Proliferation through Downregulation in Soft Tissue Sarcomas. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
92	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 478-487	40	148
91	Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EClinicalMedicine</i> , <b>2019</b> , 9, 35-43	11.3	28

90	Pazopanib in the treatment of advanced solitary fibrous tumour - AuthorsReply. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e128	21.7	1
89	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1252-1262	21.7	34
88	Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus. <i>Sarcoma</i> , <b>2019</b> , 2019, 4351308	3.1	1
87	Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). <i>Oncologist</i> , <b>2019</b> , 24, e338-e346	5.7	24
86	In Reply. <i>Oncologist</i> , <b>2019</b> , 24, e401-e402	5.7	
85	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , <b>2019</b> , 24, e536-e541	5.7	12
84	Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?. <i>Future Oncology</i> , <b>2019</b> , 15, 17-23	3.6	2
83	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 134-144	21.7	58
82	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , <b>2018</b> , 93, 28-36	7.5	31
81	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , <b>2018</b> , 4, e180219	13.4	46
80	Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 468-475	4.3	11
79	Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5239-5249	12.9	16
78	Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. <i>Oncotarget</i> , <b>2018</b> , 9, 17576-17588	3.3	1
77	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. <i>Targeted Oncology</i> , <b>2018</b> , 13, 81-87	5	6
76	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , <b>2018</b> , 23, 62-70	5.7	42
75	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv79-iv95	10.3	223
74	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. <i>Clinical Sarcoma Research</i> , <b>2018</b> , 8,	2.5	3
73	Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv68-iv78	10.3	207

72	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv51-iv67	10.3	316
71	Options for treating different soft tissue sarcoma subtypes. <i>Future Oncology</i> , <b>2018</b> , 14, 25-49	3.6	14
70	Tumores del estroma gastrointestinal: breve actualizaci3n y consenso de la SEAP-SEOM sobre diagn3stico patol3gico y molecular. <i>Revista Espanola De Patologia</i> , <b>2017</b> , 50, 89-99	1.2	
69	GEIS guidelines for gastrointestinal sarcomas (GIST). <i>Cancer Treatment Reviews</i> , <b>2017</b> , 55, 107-119	14.4	64
68	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 812-822	21.7	259
67	Review of past and present clinical cases with a view to future treatment options. <i>Future Oncology</i> , <b>2017</b> , 13, 11-28	3.6	2
66	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1230-1242	10.3	108
65	Disruption of TCF/ECatenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1166-1176	6.1	10
64	The importance of treating by histological subtype in advanced soft tissue sarcoma. <i>Future Oncology</i> , <b>2017</b> , 13, 23-31	3.6	9
63	Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 536-545	3.6	10
62	Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 1113-1131	3.5	23
61	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Oncology</i> , <b>2017</b> , 28, 2994-2999	10.3	33
60	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1278-1285	8.7	25
59	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). <i>British Journal of Cancer</i> , <b>2017</b> , 117, 767-774	8.7	12
58	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , <b>2017</b> , 28, 2399-2408	10.3	174
57	Current and future systemic treatment options for advanced soft-tissue sarcoma beyond anthracyclines and ifosfamide. <i>Cancer Translational Medicine</i> , <b>2017</b> , 3, 20	0.3	2
56	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2283-2288	10.3	64
55	sarcoma Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, i587	10.3	13

54	Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. <i>Clinical Sarcoma Research</i> , <b>2016</b> , 6, 10	2.5	1
53	Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 133-46	3.5	31
52	Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155946	3.7	9
51	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). <i>Oncotarget</i> , <b>2016</b> , 7, 67033-67046	3.4	19
50	Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor. <i>Current Opinion in Oncology</i> , <b>2016</b> , 28, 338-44	4.2	4
49	SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). <i>Clinical and Translational Oncology</i> , <b>2016</b> , 18, 1213-1220	3.6	24
48	SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). <i>Clinical and Translational Oncology</i> , <b>2016</b> , 18, 1221-1228	3.6	13
47	Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2294-302	2.2	50
46	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , <b>2015</b> , 20, 823-30	5.7	23
45	Indirect comparisons in cost-effectiveness analysis: are we being naïve?. <i>Clinical and Translational Oncology</i> , <b>2015</b> , 17, 85-6	3.6	1
44	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3628-34	2.2	42
43	RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas. <i>Cancer Investigation</i> , <b>2015</b> , 33, 440-50	2.1	19
42	Trabectedin clinical cases: use according to indication in diverse clinical scenarios. <i>Future Oncology</i> , <b>2015</b> , 11, 15-24	3.6	9
41	Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1611-7	7.5	48
40	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and the Japanese Sarcoma Group. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3628-34	2.2	102
39	Building a global consensus approach to chordoma: a position paper from the medical and patient community. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e71-83	21.7	269
38	Giant cell tumour of bone: new treatments in development. <i>Clinical and Translational Oncology</i> , <b>2015</b> , 17, 419-30	3.6	57
37	Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 2948-57	3.1	35

36	Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124239	3.7	5
35	Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 287-94	4.3	8
34	GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 883-98	3.5	33
33	Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. <i>Acta Oncologica</i> , <b>2014</b> , 53, 1173-9	3.2	45
32	Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein. <i>Journal of Nutritional Biochemistry</i> , <b>2014</b> , 25, 429-38	6.3	19
31	MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 249-59	6.1	23
30	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , <b>2013</b> , 24, 817-23	10.3	55
29	Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. <i>PLoS ONE</i> , <b>2012</b> , 7, e37735	3.7	34
28	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , <b>2012</b> , 118, 5857-66	6.4	73
27	SEOM guidelines for gastrointestinal stromal sarcomas (GIST). <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 536-40	3.6	4
26	SEOM clinical guidelines for the management of adult soft tissue sarcomas. <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 541-4	3.6	10
25	Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. <i>Sarcoma</i> , <b>2012</b> , 2012, 740279	3.1	47
24	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2012</b> , 23 Suppl 7, vii100-9	10.3	58
23	Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 850-6	2.2	128
22	Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2012</b> , 23 Suppl 7, vii49-55	10.3	132
21	Adjuvant therapy in primary GIST: state-of-the-art. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2776-2781	10.3	54
20	Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4458-64	12.9	143
19	Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action. <i>European Journal of Pharmacology</i> , <b>2011</b> , 658, 57-64	5.3	13



18	Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2528-33	2.2	187
17	Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1552-1557	10.3	50
16	Clinical implications of KIT and PDGFRA genotyping in GIST. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 670-6	3.6	25
15	Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value. <i>International Journal of Laboratory Hematology</i> , <b>2010</b> , 32, 582-9	2.5	7
14	Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1893-8	2.2	54
13	Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 766-76	59.2	387
12	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. <i>Lancet Oncology</i> , <b>2009</b> , 10, 1045-52	21.7	352
11	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. <i>Modern Pathology</i> , <b>2008</b> , 21, 476-84	9.8	148
10	Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). <i>Sarcoma</i> , <b>2006</b> , 2006, 26986	3.1	6
9	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 1797-802	8.7	2
8	Anal canal duplication: a retrospective analysis of 12 cases from two European pediatric surgical departments. <i>Pediatric Surgery International</i> , <b>2006</b> , 22, 967-73	2.1	28
7	Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6190-8	2.2	291
6	A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. <i>Cancer</i> , <b>2005</b> , 104, 1706-12	6.4	79
5	A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. <i>Clinical and Translational Oncology</i> , <b>2005</b> , 7, 66-73	3.6	8
4	Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). <i>Sarcoma</i> , <b>2005</b> , 9, 127-32	3.1	27
3	Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). <i>Journal of Neuro-Oncology</i> , <b>2004</b> , 70, 359-69	4.8	25
2	Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Oncology</i> , <b>1998</b> , 9, 871-6	10.3	51
1	Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Oncology</i> , <b>1998</b> , 9, 783-5	10.3	3

